Colorectal Cancer Screening and Diagnostic Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Screening (Stool-Based Test, Colonoscopy and Sigmoidoscopy, others), by Diagnostic (Biomarker Test, Colonoscopy), by End User (Hospitals and Clinics, Clinical Laboratories, others), by region, and Competition Forecast
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationColorectal Cancer Screening and Diagnostic Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Screening (Stool-Based Test, Colonoscopy and Sigmoidoscopy, others), by Diagnostic (Biomarker Test, Colonoscopy), by End User (Hospitals and Clinics, Clinical Laboratories, others), by region, and Competition Forecast
| Forecast Period | 2024-2028 |
| Market Size (2022) | 9.47 billion |
| CAGR (2023-2028) | 5.20% |
| Fastest Growing Segment | Hospitals & clinics |
| Largest Market | North America |
Market Overview
Global Colorectal Cancer Screening and Diagnostic Market has valued at USD 9.47 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.20% through 2028.
The establishment and promotion of colorectal cancer screening guidelines by healthcare authorities and professional organizations encourage individuals to undergo regular screening, driving market growth.
Key Market Drivers
Advancements in Technology
High-definition (HD) colonoscopy uses advanced imaging technology to provide clearer and more detailed images of the colon. This improves the detection of precancerous polyps and early-stage colorectal cancer during colonoscopy procedures. CT colonography is a non-invasive imaging technique that uses computed tomography (CT) scans to create three-dimensional images of the colon. It offers an alternative to traditional colonoscopy and is less invasive, making it more patient-friendly. Magnification endoscopy involves using specialized endoscopes that can magnify the colon's surface. This technology helps healthcare providers get a closer look at suspicious areas and enhances the detection of abnormalities. Narrow Band Imaging (NBI) is an endoscopic technology that uses specific wavelengths of light to enhance the visualization of blood vessels and surface structures in the colon. It aids in the detection of abnormalities that may not be visible with standard white light. Chromoendoscopy involves applying contrast agents or dyes to the colon's surface during endoscopy. This highlights abnormal tissue and improves the detection of precancerous lesions. AI and machine learning algorithms are being developed to assist healthcare providers in analyzing colonoscopy and imaging data. These algorithms can help identify and characterize polyps and lesions, reducing the risk of missed diagnoses. Research is ongoing in the development of blood-based tests that detect specific biomarkers associated with colorectal cancer. These tests aim to provide a non-invasive and convenient screening option.
Stool-based tests like fecal immunochemical tests (FIT) and DNA stool tests have evolved with improved sensitivity and specificity. They detect blood or genetic mutations associated with colorectal cancer in stool samples. Advances in molecular diagnostics have led to the identification of genetic and molecular markers associated with colorectal cancer. These markers can be used for early detection and personalized treatment strategies. Liquid biopsies involve analyzing blood or other bodily fluids for circulating tumor DNA (ctDNA) or other biomarkers. They have the potential to detect colorectal cancer and monitor treatment response. Telemedicine allows for remote consultations and discussions of colorectal cancer screening and diagnostic results. Telepathology enables pathologists to review tissue samples remotely, improving access to expertise. 3D printing technology has been used to create anatomical models of the colon and rectum, aiding in surgical planning and education for both patients and healthcare providers. Mobile apps and digital platforms are being developed to educate patients about colorectal cancer, remind them of screening appointments, and provide post-screening support. Data analytics and EHRs help healthcare providers track and manage patient screening histories, identify high-risk individuals, and improve overall healthcare management. This factor will help in the development of
Increasing Colorectal Cancer Incidence
Colorectal cancer is more common in older individuals, and as the population ages, there is a natural increase in the number of cases. The risk of developing colorectal cancer increases significantly after the age of 50. Demographic shifts, including population growth and changes in age distribution, can lead to a higher overall number of cancer cases, including colorectal cancer. Unhealthy lifestyle choices, such as diets high in processed foods, red meat, and low in fiber, along with sedentary behavior, obesity, and smoking, can increase the risk of colorectal cancer. Diets that are low in fruits, vegetables, and whole grains, which are rich in fiber and protective against colorectal cancer, contribute to the increasing incidence. The rise in obesity rates, particularly in developed countries, is associated with an increased risk of colorectal cancer. Lack of physical activity and sedentary behaviors are linked to an elevated risk of colorectal cancer. Excessive alcohol consumption is a known risk factor for colorectal cancer, and increased alcohol intake in some populations contributes to the rising incidence. Environmental factors, including exposure to certain toxins and pollutants, can contribute to an increased cancer risk. While most colorectal cancer cases are sporadic, there is a hereditary component to some cases. Genetic factors, family history, and certain inherited conditions can increase susceptibility. Despite the availability of effective screening methods, not all eligible individuals undergo regular colorectal cancer screening. This can lead to late-stage diagnoses and an increase in cases. Disparities in access to healthcare services, particularly in underserved communities or regions with limited healthcare infrastructure, can result in delayed diagnosis and treatment. In some cases, increased awareness and early detection efforts may lead to the identification of previously undiagnosed cases. This factor will pace up the demand of Global Colorectal Cancer Screening and Diagnostic Market.
Rising Awareness Campaigns
wareness campaigns provide essential information about colorectal cancer, including its risk factors, symptoms, and the value of early detection. Educated individuals are more likely to seek out screening options. These campaigns help dispel common myths and misconceptions about colorectal cancer, reducing fear and stigma associated with the disease. This, in turn, encourages more people to consider screening. Awareness campaigns often emphasize the importance of adhering to recommended screening guidelines. This helps individuals understand when they should start screening and which methods are suitable for them. Campaigns inform individuals about the various colorectal cancer screening methods found at, such as colonoscopy, stool-based tests, and virtual colonoscopy. This information allows people to make informed choices based on their preferences and risk factors. Campaigns encourage individuals to discuss colorectal cancer screening with their healthcare providers. Open dialogues with healthcare professionals can lead to informed decisions about screening. By raising awareness about the importance of screening, these campaigns aim to boost screening rates, especially among those who may not have previously considered it. Awareness campaigns often target high-risk populations, such as those with a family history of colorectal cancer or specific genetic factors. By reaching these groups, campaigns can drive more targeted screening efforts.
Early detection of colorectal cancer is associated with better treatment outcomes. Awareness campaigns emphasize the benefits of catching the disease at an early, more treatable stage. Some individuals may face barriers to colorectal cancer screening, such as cost or lack of access to healthcare facilities. Awareness campaigns often address these barriers and provide information about found at resources and assistance programs. By providing information and resources, awareness campaigns empower individuals to take control of their health and make informed decisions about their colorectal cancer screening and diagnostic needs. Awareness campaigns also provide support and resources for colorectal cancer survivors, helping them navigate post-treatment care and monitoring. Some awareness campaigns engage in advocacy efforts to promote policies that improve access to screening and reduce barriers. Awareness campaigns can have a global impact, raising awareness about colorectal cancer in regions where screening rates are low and encouraging governments and healthcare systems to invest in screening programs. This factor will accelerate the demand of
Key Market Challenges
False Positives and Over diagnosis
False positives occur when a screening test suggests the presence of colorectal cancer or precancerous lesions when they are not actually present.
Limited Screening Options in Developing Regions
Many developing regions lack the necessary healthcare infrastructure to support widespread colorectal cancer screening programs. This includes a shortage of healthcare facilities, trained professionals, and diagnostic equipment.
Key Market Trends
Shift Towards Non-Invasive Tests
Non-invasive tests, such as stool-based tests or blood tests, are generally more acceptable to patients because they do not involve invasive procedures like colonoscopy. This improved patient acceptance can lead to higher screening participation rates.
Segmental Insights
Screening Insights
In 2022, the Global Colorectal Cancer Screening and Diagnostic Market largest share was held by Stool-Based Test segment and is predicted to continue expanding over the coming years.
Diagnostics Insights
In 2022, the Global Colorectal Cancer Screening and Diagnostic Market dominated by Colonoscopy segment and is predicted to continue expanding over the coming years.
End User Insights
In 2022, the Global Colorectal Cancer Screening and Diagnostic Market largest share was dominated by Clinical Laboratories segment in the forecast period and is predicted to continue expanding over the coming years.
Regional Insights
The North America region dominates the Global Colorectal Cancer Screening and Diagnostic Market in 2022. North America has a relatively high prevalence of colorectal cancer, which necessitates robust screening and diagnostic efforts. Factors such as diet, lifestyle, and an aging population contribute to this prevalence.
Recent Developments
- In May 2023, The GIF-1100 gastrointestinal videoscope is indicated foruse in the upper digestive tract, which includes the oesophagus, stomach, andduodenum, and the CF-HQ1100DL/I colonovideoscope is indicated for use in thelower digestive tract in surgical procedures, according to Olympus, a globaltechnology leader in designing and delivering innovative solutions for medicaland surgical procedures. In order to diagnose, treat, and observe diseases and disorders of theupper and lower GI tract, including acid reflux, ulcers, Crohn's disease,Celiac disease, and colorectal cancer, doctors employ Olympus® GI endoscopyequipment. A screening colonoscopy, in which a doctor examines the lining ofthe colon and can remove any possibly malignant growths, or polyps, is one ofthe most frequent applications of an endoscope. The introduction of new imagingtechnologies could help doctors spot anomalies.
- In June 2022, A revolutionary, non-invasive, at-home screening testcalled ColoClear by Circle (ColoClear) has been developed by Prenetics GroupLimited, a world authority in genomic and diagnostic testing, to find earlyindications of colorectal cancer. In Hong Kong, colorectal cancer ranks secondin terms of incidence, with 15.8% of all new cases in 2019. The ground-breakingtest is the first line of defence against one of the most preventablemalignancies, which can be treated in 90% of cases when found early andcombines cutting-edge stool DNA technology with a faecal immunochemical test(FIT). ColoClearwas introduced in collaboration with New Horizon Health (HKEX6606), a leaderin biotechnology for early cancer screening technologies. The cutting-edgescreening technique employs numerous DNA indicators and blood cells to identifyhuman stool.
- In October 2020, the first and only non-invasive stool DNA screeningtest for colorectal cancer to receive FDA approval, Cologuard, is beingpromoted by Exact Sciences Corp. and Pfizer Inc. through an extension andmodification of their existing partnership. According to the conditions of thestatewide agreement, Pfizer will keep up the marketing and related assistancefor Cologuard and work alongside Exact Sciences to spread awareness ofCologuard among patients, doctors, and healthcare organisations. The COVID-19 epidemic hasbrought to light the importance of accessible, reliable cancer testingalternatives. Early detection of colorectal cancer can significantly improveoutcomes, and with more than one million screening colonoscopies expected to bemissed this year, there is an urgent need to raise screening rates. Theaccurate at-home colon cancer screening alternative Cologuard is in a uniqueposition to provide screening both now and after the pandemic has passed.
Key Market Players
- Clinical Genomics Technologies Pty Ltd.
- Danaher Corporation
- DiaCarta, Inc.
- Eiken Chemical Co., Ltd.
- Epigenomics AG
- Freenome Holdings, Inc.
- Guardant Health, Inc.
- Lepu Medical Technology (Beijing) Co., Ltd.
- NovigenixSA
- FUJIFILMHoldings Corporation
- OlympusCorporation
- QuidelOrthoCorporation
| By Screening | By Diagnostics | By End User | By Region | By Region |
| Stool-Based Test Colonoscopy and Sigmoidoscopy others | Biomarker Test Colonoscopy | Hospitals and Clinics Clinical Laboratories Others | North America Asia-Pacific Europe South America Middle East & Africa | Saudi Arabia UAE Qatar Kuwait Bahrain Rest of Middle East |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy